Table 1.
General characteristics of fallers and matched controls.
| Fallers (n = 210) |
Controls (n = 410) |
P value | |
|---|---|---|---|
| Age, years | 73.7 ± 8.41 | 73.6 ± 8.41 | 0.965 |
| Male, n (%) | 125 (59.5%) | 240 (58.5%) | 0.813 |
| Height, cm | 159.9 ± 9.82 | 160.3 ± 9.16 | 0.793 |
| Body weight, kg | 58.4 ± 11.66 | 60.5 ± 11.50 | 0.009 |
| Body mass index, kg/m2 | 22.8 ± 3.87 | 23.5 ± 3.69 | 0.009 |
| Smoking, n (%) | 28 (13.3%) | 34 (8.3%) | 0.087 |
| Alcohol consumption, n (%) | 27 (12.9%) | 54 (13.2%) | 0.913 |
| Comorbidities | |||
| Hypertension | 123 (58.6%) | 224 (54.6%) | 0.35 |
| Diabetes mellitus | 79 (37.6%) | 112 (27.3%) | 0.009 |
| Dyslipidemia | 19 (9.0%) | 43 (10.5%) | 0.572 |
| Heart disease | 33 (15.7%) | 60 (14.6%) | 0.721 |
| Cerebrovascular disease | 22 (10.5%) | 47 (11.5%) | 0.711 |
| History of malignancy | 53 (25.2%) | 103 (25.1%) | 0.975 |
| Chronic lung disease | 16 (7.9%) | 27 (6.6%) | 0.632 |
| History of tuberculosis | 12 (5.7%) | 20 (4.9%) | 0.656 |
| Chronic kidney disease | 14 (6.7%) | 29 (7.1%) | 0.85 |
| Chronic liver disease | 8 (3.8%) | 9 (2.2%) | 0.244 |
| Osteoporosis | 8 (3.8%) | 29 (7.1%) | 0.104 |
| Cognitive impairment | 14 (6.7%) | 11 (2.7%) | 0.017 |
| Parkinson’s disease | 8 (3.8%) | 6 (1.5%) | 0.063 |
| Psychiatric disease | 8 (3.8%) | 15 (3.7%) | 0.925 |
| Benign prostate hyperplasia* | 16 (12.8%) | 38 (15.8%) | 0.491 |
| Number of comorbidities | 0.418 | ||
| 0 | 18 (8.6%) | 47 (11.5%) | |
| 1 | 112 (53.3%) | 223 (54.4%) | |
| ≥ 2 | 80 (38.1%) | 140 (34.1%) | |
| Visual impairment | 56 (26.7%) | 98 (23.9%) | 0.451 |
| Hearing impairment | 18 (8.6%) | 37 (9.0%) | 0.851 |
| Sleep disorder | 13 (6.2%) | 26 (6.3%) | 0.596 |
| Length of hospital stay | 19.5 ± 18.8 | 11.7 ± 9.53 | < 0.001 |
| Discharge disposition | < 0.001 | ||
| Home | 137 (65.2%) | 343 (83.7%) | |
| Hospital transfer | 63 (30.0%) | 46 (11.2%) | |
| Death | 9 (4.3%) | 10 (2.4%) | |
Data are presented as means (standard deviation) or frequencies (percentage), as appropriate. *The prevalence of benign prostate hyperplasia was calculated in male subjects.